Current Use of Hematopoietic Cell Transplantation in Hematologic Malignancies

Dear Colleagues,

Allogeneic hematopoietic cell transplantation (allo-HCT) is a vital treatment for various hematologic malignancies. This Special Issue aims to provide a comprehensive overview of the current landscape of allo-HCT, focusing on key topics such as patient selection, conditioning regimens and the integration of immunotherapies and targeted treatments that are reshaping care practices.

Emphasis will be placed on the importance of minimal residual disease (MRD) as a critical marker for predicting transplant outcomes. Advances in MRD detection techniques allow for more precise monitoring, enabling clinicians to identify patients who may benefit from pre-emptive treatments to reduce relapse rates. We will also evaluate different prophylaxis regimens for preventing disease and managing graft-versus-host disease.

Additionally, we welcome real-world data studies that provide insights into the safety, effectiveness sand practicality of allo-HCT across various patient populations. Investigations exploring GVHD prophylaxis and the safety and effectiveness of using specific transplant platforms, focusing on preventing infectious complications and enhancing patient care, are also sought for this present collection.

By fostering dialogue among researchers and clinicians, this Special Issue seeks to enhance our understanding of the complexities of allo-HCT in hematologic malignancies and improve patient care.

We welcome research articles and reviews that highlight both basic and clinical aspects of HCT in this dynamic field.

Dr. Marina Díaz-Beyá
Dr. Maria Queralt Salas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.